Oct 2026· Biology· Vol 15, pp. 1912· 0 citations· 35 references
TL;DR
Serum β-endorphin levels in patients with BPD are investigated, suggesting that peripheral β-endorphin is unlikely to represent a trait biomarker of BPD but may be associated with response to psychotherapy, although its potential clinical relevance requires validation in larger independent cohorts.
Abstract
Borderline personality disorder (BPD) is characterized by emotion dysregulation, interpersonal dysfunction, and frequent non-suicidal self-injury (NSSI). Altered pain sensitivity in BPD has raised interest in the possible role of the endogenous opioid system, but only a few studies have explored β-endorphin, one of the major endogenous opioid peptides, in this disorder. Here we investigated serum β-endorphin levels in patients with BPD, their association with clinical features, and their longitudinal changes during psychotherapy. Forty-nine patients with BPD enrolled in the CLIMAMITHE randomized controlled trial and 25 age- and sex-matched unaffected controls were included. Serum β-endorphin concentrations were measured by ELISA at baseline in all participants and also after 6 and 12 months of treatment in patients receiving metacognitive interpersonal therapy or structured clinical management. Baseline β-endorphin levels did not differ between patients and controls and were not associated with symptom severity, interpersonal functioning, attachment style, psychotropic treatment, or NSSI. No overall longitudinal changes were observed during psychotherapy. However, responders showed a significant increase in β-endorphin levels from T0 to T12 (p = 0.016), whereas non-responders remained unchanged. Moreover, responders exhibited significantly lower baseline β-endorphin concentrations than non-responders (p = 0.001), and baseline levels showed potential discriminative value for treatment response (AUC = 0.806, p = 0.002) and correlated with changes in emotion dysregulation during treatment, measured through the DERS (r = 0.344, p = 0.040). In conclusion, these findings suggest that peripheral β-endorphin is unlikely to represent a trait biomarker of BPD but may be associated with response to psychotherapy, although its potential clinical relevance requires validation in larger independent cohorts.
BACKGROUND
Borderline personality disorder (BPD) is a complex disorder associated with severe interpersonal instability and common relationship problems. Oxytocin has emerged as a candidate neuropeptide, with cross-sectional studies showing reduced levels in individuals with BPD. Longitudinal data - particularly in ado...
Sibille Steiner, C. Reichl, S. Sele et al.· Psychoneuroendocrinology· 0 citations
Early-onset schizophrenia (EOS) is a severe psychiatric disorder with poor long-term outcomes. It offers a unique opportunity to examine the neurobiological mechanisms of schizophrenia without the confounding effects of adult environmental factors. Oxytocin (OXT), a neuropeptide involved in social and emotional regulat...
BACKGROUND
Borderline personality disorder (BLPD) is a complex and debilitating psychiatric condition with high prevalence and clinical and psychosocial burden. Psychotherapy is the recommended first-line treatment but, in real-world clinical practice, most individuals with BLPD are prescribed psychotropic medications,...
M. D'Incalci, C. M. Congedo, G. Agostoni et al.· Journal of Clinical Psychoph...· 0 citations
BACKGROUND
Elevated borderline features (EBF) in bipolar disorder (BD) are associated with a more severe illness course, but prospective evidence remains limited, particularly in Asian populations. We examined the clinical correlates and 6-month depressive symptom course of EBF in Korean patients with BD.
METHODS
Par...
Eunhee Jang, Y. Shin, M. Choi et al.· Journal of Affective Disorde...· 0 citations
Background
: Chronic stress can disrupt the adaptive mechanism consisting of negative regulation of the hypothalamicpituitary-adrenal (HPA) axis by endogenous neurosteroids, thereby contributing to the development of stress-related affective disorders. However, the dynamics of neurosteroid status during treatment ha...
S. A. Semin, R. Akhapkin, N. Kudryashov et al.· Psychiatry· 0 citations
Objective It remains unclear whether specific borderline personality pathology (BPP) traits differentially relate to problematic alcohol use (PAU) across mood disorder diagnoses. This study examined diagnosis-specific patterns of association between BPP and PAU in major depressive disorder (MDD), bipolar I disorder (BD...
J. Kim, Jakyung Lee, Hyeona Yu et al.· Psychiatry Investigation· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.